Regulatory Approval, Requisite Consents and Expiration of Consent Solicitations, and Stock Price Movements - Research Report on Thermo Fisher, Endo, Perrigo, Keryx, and Waters Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, December 4, 2013 NEW YORK, December 4, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Thermo Fisher Scientific Inc. (NYSE: TMO), Endo Health Solutions Inc. (NASDAQ: ENDP), Perrigo Company (NYSE: PRGO), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), and Waters Corporation (NYSE: WAT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Thermo Fisher Scientific Inc. Research Report On November 26, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) announced that the Company has received approval from the European Commission for its pending acquisition of Life Technologies Corporation. Thermo Fisher added that it has committed to divest its cell culture (sera and media), gene modulation, and magnetic beads businesses to expedite the approval. Thermo Fisher informed that the acquisition remains subject to additional regulatory approvals, including the US Federal Trade Commission's approval. The Company informed that it expects that additional divestitures will not be required in order to receive U.S. approval. Thermo Fisher further informed that it is working with the regulatory agencies to complete the transaction as soon as possible, and continues to expect the transaction to close in early 2014. The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/45ed_TMO -- Endo Health Solutions Inc. Research Report On November 27, 2013, Endo Health Solutions Inc. (Endo) announced that according to the tabulation agent, requisite holders of its senior notes (the Notes) (including 7% Senior Notes due 2019, 7.00% Senior Notes due 2020, 7¼% Senior Notes due 2022) had consented to the proposed amendments to the indentures governing the Notes (the Proposed Amendments), upon terms and subject to the conditions set forth in the Consent Solicitation statement, dated November 19, 2013 (the Statement). The Company informed that it received valid consents in respect of a majority in aggregate principal amount of each series of the outstanding Notes as of 5:00 p.m. New York City time, on November 27, 2013. The Company, therefore, reported that it intends to enter into supplemental indentures, by and among Endo, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, to each of the indentures governing the Notes, reflecting the Proposed Amendments. Endo further informed that it will pay eligible holders, who have validly delivered and not revoked consents on or prior to the Expiration Date, a cash payment equal to $2.50 per $1,000 aggregate principal amount of each series of Notes consented (the Consent Fee), subject to terms and conditions set forth in the Statement. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/059c_ENDP -- Perrigo Company Research Report On November 29, 2013, Perrigo Company's (Perrigo) stock rose 0.06%, ending the day at $155.89. Over the previous three trading sessions, shares of Perrigo declined 0.35% compared to the S&P 500 which gained 0.18% during the same period. The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/4168_PRGO -- Keryx Biopharmaceuticals, Inc. Research Report On November 29, 2013, Keryx Biopharmaceuticals, Inc.'s (Keryx Biopharmaceuticals) stock gained 4.59%, ending the day at $13.89. Over the previous three trading sessions, shares of Keryx Biopharmaceuticals gained 8.86%, compared to the Nasdaq Composite which gained 1.64% during the same period. The Full Research Report on Keryx Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/27d2_KERX -- Waters Corporation Research Report On November 27, 2013, Waters Corporation (Waters) and the Biochemical Society announced the opening of registration for the Biochemical Society's Quantitative Proteomics Training Day and the ProteoMMX 3.0 Symposium. According to the Company, the Quantitative Proteomics Training Day is aimed at researchers who seek to gain familiarity with the field of quantitative proteomics. On the other hand, Waters informed that ProteoMMX 3.0 is dedicated to current thinking and state-of-the-art research in quantitative proteomics. Waters further informed that these are consecutive events to be held on March 24, 2014 to March 27, 2014, in Chester, England. The Full Research Report on Waters Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2fff_WAT ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas; +1-310-496-8071 (North America)
Alibaba Indicated to Start Trading at $87 to $89
Regulatory Approval, Requisite Consents and Expiration of Consent Solicitations, and Stock Price Movements - Research Report on
Press spacebar to pause and continue. Press esc to stop.